Testing for deficient mismatch repair and microsatellite instability : A focused update

Rüschoff J, Schildhaus HU, Rüschoff JH, Jöhrens K, Bocker Edmonston T, Dietmaier W, et al. Testing for deficient mismatch repair and microsatellite instability : A focused update. Pathologie (Heidelb.) 2023 Nov;44(Suppl 2):61-70. doi:10.1007/s00292-023-01208-2. Epub 2023 Oct 24

EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ®)

Petersen I, et al. EGFR immunohistochemistry as biomarker for antibody-based therapy of squamous NSCLC – Experience from the first ring trial of the German Quality Assurance Initiative for Pathology (QuIP ®). Pathol Res Pract 2017 Sept;213(12). doi: 10.1016/j.prp.2017.09.021

Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer

Scheel AH, et al. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. Histopathology 2018 Feb;72(3):449-459. doi: 10.1111/his.13375

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

Scheel AH, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 2016 Oct;29(10):1165-72. doi:10.1038/modpathol.2016.117

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib

Thunnissen E, et al. ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer 2019 Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023